Efficacy of sequential ipilimumab monotherapy versus best supportive care for unresectable locally advanced/metastatic gastric or gastroesophageal junction cancer

Clinical Cancer Research

Volumn 23, Issue 19, 2017, Pages 5671-5678

  Bang, Yung Jue ^a   Cho, Jae Yong ^b   Kim, Yeul Hong ^c   Kim, Jin Won ^d   Bartolomeo, Maria Di ^e   Ajani, Jaffer A ^f   Yamaguchi, Kensei ^g   Balogh, Agnes ^h   Sanchez, Teresa ^h   Moehler, Markus ⁱ  

^a Seoul National University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Korea University College of Medicine   (South Korea)

^d Seoul National University Bundang Hospital   (South Korea)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f UNIVERSITY OF TEXAS   (United States)

^g SAITAMA CANCER CENTER   (Japan)

^h BRISTOL MYERS SQUIBB   (United States)

ⁱ JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; FLUOROPYRIMIDINE; FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IPILIMUMAB; OXALIPLATIN; ANTINEOPLASTIC AGENT;

ACUTE HEPATITIS; ADULT; ADVANCED CANCER; ARTICLE; ASTHENIA; CANCER GROWTH; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COLITIS; CONTROLLED STUDY; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG SAFETY; ENDOCRINE DISEASE; FATIGUE; FEMALE; GASTROESOPHAGEAL JUNCTION CANCER; GASTROINTESTINAL DISEASE; HAND FOOT SYNDROME; HUMAN; HYPOPITUITARISM; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYALGIA; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SENSORY NEUROPATHY; STOMACH CANCER; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; ADVERSE DRUG REACTION; AGED; CLASSIFICATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; ESOPHAGUS TUMOR; GASTROESOPHAGEAL JUNCTION; MIDDLE AGED; PATHOLOGY; STOMACH TUMOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; IPILIMUMAB; MALE; MIDDLE AGED; STOMACH NEOPLASMS;

EID: 85032002887     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-17-0025     Document Type: Article

References (26)

1. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. Cancer Fact Sheets: Stomach Cancer. Lyon, France: International Agency for Research on Cancer. [2016; cited 2016 Jul 14]. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
2. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 2005;241:27–39.
3. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687–97.
4. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011;29:3968–76.
5. Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 2013;14: 481–9.
6. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24:4991–7.
7. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008;9: 215–21.
8. Hecht JR, Bang YJ, Qin SK, Chung HC, Xu JM, Park JO, et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC–A randomized phase III trial. J Clin Oncol 2016; 34:443–51.
9. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gor-bunova V, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 2010;28: 1547–53.
10. Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 2013;14:490–9.
11. Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014;383:31–9.
12. Kang JH, Lee SI, Lim DH, Park KW, Oh SY, Kwon HC, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 2012;30:1513–8.
13. Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol 2014; 15:78–86.
14. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014;15:1224–35.
15. Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun 2013;13:5.
16. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711–23.
17. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517–26.
18. Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012;30:2046–54.
19. Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 2013;24:75–83.
20. Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007;30:825–30.
21. Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol 2013;24:1813–21.
22. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994;1:405–13.
23. Opdivo (nivolumab) Princeton, NJ: Bristol-Myers Squibb Co; 2017.
24. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, et al. CTLA-4 blockade with ipilimumab: long-term followup of 177 patients with metastatic melanoma. Clin Cancer Res 2012;18:2039–47.
25. Saenger YM, Li Y, Chiou KC, Chan B, Rizzuto G, Terzulli SL, et al. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma. Cancer Res 2008;68:9884–91.
26. Janjigian YY, Bendell JC, Calvo E, Kim JW, Ascierto PA, Sharma P, et al. CheckMate-032: phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC). ASCO Meeting Abstracts 2016;34 (15_suppl):4010.